MET基因的改变，包括扩增和外显子14跳跃突变，已经被确认为可执行的致癌改变。然而，肺癌中很少检测到MET融合，并且它们对治疗的敏感性还没有进行系统分析。我们筛选了来自LAVA数据库的30876名肺癌患者和来自cBioPortal数据库的7966名患者的数据。收集了携带MET融合的患者的基本人口统计学和临床信息。对一名携带新颖的EML4-MET融合的肺鳞癌患者进行了克里索替尼治疗。此外，我们还对携带MET融合的患者病例及其治疗信息进行了文献综述。研究结果表明，MET融合仅在0.2％至0.3％的肺癌患者中发现, 几乎出现在MET基因的所有外显子中。有52.6％（41/78）的患者携带基因内MET融合。克里索替尼对MET融合，包括新发现的EML4-MET融合，在多种治疗方案失败后仍然有效。这表明获得性MET融合更具有区域性选择性，通常发生在编码细胞外区域的外显子中。有趣的是，原发性MET融合和获得性MET融合的融合基因非常不同，这表明疾病的不同功能和影响。综上，MET融合很少见，其中一半是基因内融合。携带原发性或获得性MET融合的肺癌患者可以从克里索替尼治疗中受益。此外，EML4-MET是本研究中首次报道的一种新型MET融合。©2023作者。

Alterations in the MET gene, including amplifications and exon 14 skipping mutations, have been identified as actionable oncogenic alterations. However, MET fusions are rarely detected in lung cancer, and their sensitivity to therapeutics has not been systematically analyzed.The data from 30876 lung cancer patients from the LAVA database and 7966 patients from cBioPortal database were screened. Basic demographic and clinical information for the patients harboring MET fusions were collected. A lung squamous cell cancer patient harboring a novel EML4-MET fusion was treated with crizotinib. Additionally, a literature review was performed to summarize the cases of patients harboring MET fusions and their treatment information.MET fusions were found in only 0.2% to 0.3% of lung cancer patients and appeared in almost all exons of the MET gene. Intragenic MET fusions were found in 52.6% (41/78) of the included patients. Crizotinib was effective for MET fusions, including a novel identified EML4-MET fusion, even after the failure of multiple lines of treatment. This result suggested that acquired MET fusions become more regionally selective, as they usually occurred in exons encoding the extracellular region. Interestingly, the MET-fused genes in primary MET fusions or acquired MET fusions were very different, which indicated the different functions and influences of the disease.MET fusions are rare, and half of the fusion types were intragenic fusions. Lung cancer patients harboring primary or acquired MET fusions could benefit from crizotinib. In addition, EML4-MET was first reported in this study as a novel MET fusion type.© 2023. The Author(s).